ReviewFrontiers in immunology2026
Immune ontogeny in childhood-onset systemic lupus erythematosus: effect of immune maturity on disease phenotype and therapeutic responses.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Childhood-onset systemic lupus erythematosus (cSLE) occurs during a period of significant developmental changes in the immune system, when tolerance checkpoints and regulatory networks continue to mature. Compared with adult-onset SLE (aSLE), cSLE more frequently presents with strong type I interferon activity, BAFF-induced B-cell hyperactivation, and increased activity of T follicular helper cells that promote persistent generation of autoantibodies. These changes induce an IFN-BAFF-B-cell-immune complex-complement axis positive feedback loop that can affect developmentally vulnerable organs, thus increasing the risk for early severe lupus nephritis, neuropsychiatric involvement, cytopenias, infection, and drug toxicities. We synthesize evidence for an immune ontogeny-based approach that considers altered molecular pathways, organ development, and responses to different therapeutics, and highlight that a higher genetic burden must be addressed for the effective stratification of patients. Finally, we propose a pragmatic approach to precision care based on developmental stage, immunophenotype, genetics, and long-term safety to enable the earlier onset of steroid-sparing therapy and long-term protection of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.